The Ophthalmology Therapeutics Market in APAC was worth USD 5.31 billion in 2022 and is estimated to grow at a CAGR of 8.5%, to reach USD 7.98 billion by 2027.
Ophthalmology is the branch of medicine that deals with the eye's anatomy, physiology, and diseases. Recent advancements in genetics and stem cell biology have brought several changes to the Ophthalmology Therapeutics Market.
The growing prevalence of vision impairment drives Asia Pacific Ophthalmology Therapeutics. According to a recent update by WHO, the prevalence of visual impairment is nearly 285 million globally. Of these, 246 million people have moderate to severe visual impairment. South-East Asia and the Western Pacific accounted for 73% of the total visual impairments. Other major factors driving the growth of the market include increasing awareness about the importance of detecting ophthalmic diseases as early as possible and efficient diagnostic tools.
However, stringent regulatory framework and lack of reimbursement policies are restraining the growth of the market.
This research report on the Asia Pacific Ophthalmology Therapeutics Market has been segmented and sub-segmented Market into the following categories:
By End User:
Geographically, Asia-Pacific is the fastest-growing region with a CAGR of xx% during the forecast period. Within Asia-Pacific, Japan is the largest market for Opthalmology therapeutics accounting for a share of approximately 45%, followed by China. Glaucoma is the largest indication segment accounting for a share of approximately XX%.
Prominent companies in the APAC Ophthalmology Therapeutics Market are Pfizer Inc., Allergan Inc., Alcon Inc., Merck & co. Inc., Roche Valeant, Regeneron, Santen, Bayer, Senju, Lpath, and Eye Gate Pharmaceuticals.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org